Q27756 (Q27756): Difference between revisions

@@ Property / author: Arjee Restar / qualifier @@
+affiliation: University of Washington Department of Epidemiology
@@ Property / author: Arjee Restar / qualifier @@
+affiliation: University of Washington Department of Health Systems and Population Health
@@ Property / author: Arjee Restar / qualifier @@
+affiliation: Yale School of Public Health
@@ Property / author: Arjee Restar / qualifier @@
+affiliation: Weitzman Institute
@@ Property / author: Arjee Restar / qualifier @@
+series ordinal: 1Amount 1
Unit 1
 Amount
 Unit
@@ Property / author: Arjee Restar / qualifier @@
-affiliation: University of Washington Department of Health Systems and Population Health
@@ Property / author: Arjee Restar / qualifier @@
-affiliation: Yale School of Public Health
@@ Property / author: Arjee Restar / qualifier @@
-affiliation: Weitzman Institute
@@ Property / author: Arjee Restar / qualifier @@
-series ordinal: 1Amount 1
Unit 1
 Amount
 Unit

Revision as of 19:23, 28 October 2024

No description defined

Using stated preference methods to design gender-affirming long-acting PrEP programs for transgender and nonbinary adults.

Language	Label	Description	Also known as
English	No label defined	No description defined	Using stated preference methods to design gender-affirming long-acting PrEP programs for transgender and nonbinary adults.

Statements

1 reference

Using stated preference methods to design gender-affirming long-acting PrEP programs for transgender and nonbinary adults. (English)

1 reference

stated in

PubMed

abstract

Integrating gender-affirming care with biomedical HIV prevention could help address the disproportionate HIV risk experienced by transgender and nonbinary (trans) adults. (English)

1

2024

1 reference

This discrete choice experiment assesses and identifies the most important programming factors influencing the decisions of trans adults to use injectable long-acting HIV pre-exposure prophylaxes (LA-PrEP). (English)

2

2024

1 reference

From March to April 2023 n = 366 trans adults in Washington state chose between four different choice profiles that presented hypothetical programs (each comprised of 5 attributes with 4 levels). (English)

3

2024

1 reference

We analyzed ranked choice responses using a mixed rank-ordered logit model for main effects. (English)

4

2024

1 reference

Respondents preferred to receive LA-PrEP from a gender-affirming care provider and a co-prescription for both oral and injectable hormones. (English)

5

2024

1 reference

Trans adults strongly favored 12-month protection and injection in the upper arm. (English)

6

2024

1 reference

No strong preferences emerged surrounding the type of health facility offering the gender-affirming LA-PrEP program. (English)

7

2024

1 reference

Our findings show that integrating and leveraging gender-affirming health systems, inclusive of medical services such as hormone therapy, with HIV biomedical products like LA-PrEP is strongly preferred and influential to trans adults' decision to use LA-PrEP. (English)

8

2024

1 reference

Leveraging choice-based design experiments provides informative results for optimizing gender-affirming LA-PrEP programming tailored to trans adults. (English)

9

2024

1 reference